PCN64 CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)

Nov 1, 2007, 00:00
10.1016/S1098-3015(10)65222-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)65222-9/fulltext
Title : PCN64 CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65222-9&doi=10.1016/S1098-3015(10)65222-9
First page :
Section Title :
Open access? : No
Section Order : 381
Categories :
Tags :
Regions :
ViH Article Tags :